| 习晓丽,叶美玲.绞股蓝总苷胶囊对非酒精性脂肪性肝病病人糖脂代谢、氧化应激水平及肝纤维化指标的影响[J].安徽医药,2022,26(4):824-828. |
| 绞股蓝总苷胶囊对非酒精性脂肪性肝病病人糖脂代谢、氧化应激水平及肝纤维化指标的影响 |
| Effects of gypenoside capsule on glycolipid metabolism, oxidative stress and liver fibrosis in patients with nonalcoholic fatty liver disease |
| |
| DOI：10.3969/j.issn.1009-6469.2022.04.042 |
| 中文关键词: 非酒精性脂肪性肝病 绞股蓝属 丙氨酸转氨酶 γ-谷氨酰转移酶 透明质酸 肝纤维化 氧化应激 |
| 英文关键词: Nonalcoholic fatty liver disease Gynostemma Alanine aminotransferase Gamma-glutamyltransferase Hyaluron-ic acid Liver fibrosis Oxidative stress |
| 基金项目: |
|
| 摘要点击次数: 1011 |
| 全文下载次数: 468 |
| 中文摘要: |
| 目的探讨绞股蓝总苷胶囊对非酒精性脂肪性肝病( NAFLD)病人的肝功能、糖脂代谢水平、肝纤维化程度以及氧化应激指标的影响。方法回顾性分析宜宾市第一人民医院 2016年 12月至 2019年 6月收治的 120例 NAFLD病人的临床资料。根据治疗方式不同将病人分成观察组与对照组，各 60例。对照组予以控制膳食热量摄入，调整膳食结构，选择适合的体育锻炼方式等基础治疗，并加用多烯磷脂酰胆碱胶囊治疗。观察组在对照组基础上加用绞股蓝总苷胶囊治疗。两组均连续治疗 3个月。于治疗前及治疗 3个月后检测肝功能、稳态模型 IR指数( HOMA-IR)、体质量指数( BMI)、脂代谢指标、肝纤维化指标及氧化应激指标。结果治疗后，观察组丙氨酸氨基转移酶酶( ALT)、天门冬氨酸氨基转移酶( AST)、 γ-谷氨酰转移酶( γ-GGT)低于对照组［( 39.82±13.66)IU/L比( 49.40±11.85)IU/L，(32.36±8.97)IU/L比( 44.46±10.64)IU/L，(43.21±11.78)IU/L比( 57.79± 9.47)IU/L，P<0.05］观察组胰岛素并计算稳态模型 IR指数( HOMA-IR)低于对照组［( 2.54±0.55)比( 3.45±0.65)，P<0.05］；观察组总胆固醇( TC)三酰，甘油( TG)低密度脂蛋白胆固醇( LDL-C)低于对照组［(5.33±0.95)mmol/L比( 6.24±1.06)mmol/L，(1.48±0.33)mmol/L比(1.87±0.34)mmol/L2.54±0.57)mmol/L比( 3.17±0.46)mmol/L，P<0.05］，观察组高密度脂蛋白胆固醇( HDL-C)高于对照组［(1.33±0.26)mmol/L比( 0.98±0.21)mmol/L，P<0.05］；观察组透明质酸( HA)、 Ⅲ型前胶原( PCⅢ)、 Ⅳ型胶原( C-Ⅳ)、层粘连蛋白( LN)低于对照组［( 96.66±16.32)μg/L比( 154.95±21.94)μg/L，(96.89±16.81)μg/L比( 131.12±21.86)μg/L，(84.15± |
| 英文摘要: |
| Objective To investigate the effect of gypenoside capsules on liver function, glycolipid metabolism, liver fibrosis and ox idative stress in patients with nonalcoholic fatty liver disease (NAFLD).Methods The clinical data of 120 NAFLD patients admittedto The First People's Hospital of Yibin from December 2016 to June 2019 were retrospectively analyzed. According to different treat ment methods, the patients were divided into an observation group and a control group, with 60 cases in each group. The control groupwas given basic treatments such as controlling dietary calorie intake, adjusting dietary structure, choosing appropriate physical exercisemethods, and adding polyene phosphatidylcholine capsule for treatment. The observation group was additionally treated with gypeno side capsules compared to the control group. Both groups were treated continuously for 3 months. Liver function, homeostasis model IRindex (HOMA-IR), body mass index (BMI), lipid metabolism indexes, liver fibrosis indexes and oxidative stress indexes were detectedbefore and after 3 months of treatment.Results After treatment, the levels of alanine aminotransferase (ALT), aspartate aminotransfer ase (AST), and γ-glutamyltransferase (γ-GGT) in the observation group were lower than those in the control group [(39.82±13.66) IU/L vs.(49.40±11.85) IU/L, (32.36±8.97) IU/L vs. (44.46±10.64) IU/L, (43.21±11.78) IU/L vs. (57.79±9.47) IU/L, P < 0.05]. The HOMA-IR in the observation group was lower than that in the control group [(2.54±0.55) vs. (3.45±0.65), P < 0.05]. The total cholesterol (TC), tria cylglycerol (TG), and low-density lipoprotein cholesterol (LDL-C) in the observation group were lower than those in the control group [(5.33±0.95) mmol/L vs. (6.24±1.06) mmol/L, (1.48±0.33) mmol/L vs. (1.87±0.34) mmol/L, (2.54±0.57) mmol/L vs. (3.17±0.46) mmol/L, P < 0.05]. The high-density lipoprotein cholesterol (HDL-C) in the observation group was higher than that in the control group [(1.33±0.26) mmol/L vs. (0.98±0.21) mmol/L, P < 0.05]. The hyaluronic acid (HA), type Ⅲ procollagen (PCIII), type Ⅳ collagen (C-Ⅳ) and laminin (LN) levels in the observation group were lower than those in the control group [(96.66±16.32) μg/L vs. (154.95±21.94) μg/L, (96.89±16.81) μg/L vs. (131.12±21.86) μg/L, (84.15±13.57) μg/L vs. (136.96±18.86) μg/L, (73.66±15.52) μg/L vs. (104.65±20.72) μg/ L, P < 0.05]. The superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and total antioxidant capacity (T-AOC) in the observa tion group were higher than those in the control group [(112.79±11.58) mmol/L vs. (97.02±11.98) mmol/L, (170.92±25.89) U/L vs. (152.10±22.56) U/L, (40.87±3.69) U/mL vs. (28.48±4.06) U/mL, P < 0.05], and malondialdehyde (MDA) in the observation group was lower than that in the control group [(5.34±1.00) nmol/mL vs. (6.50±1.32) nmol/mL, P < 0.05].Conclusion Gypenoside capsules canimprove the disorder of glycolipid metabolism, inhibit oxidative stress, reduce the degree of liver fibrosis and protect liver cells inNAFLD patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
